In vitro susceptibilities of Bartonella and Rickettsia spp. to fluoroquinolone antibiotics as determined by immunofluorescent antibody analysis of infected Vero cell monolayers

被引:18
作者
Ives, TJ
Marston, EL
Regnery, RL
Butts, JD
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Dept Family Med, Chapel Hill, NC 27599 USA
[3] Ctr Dis Control & Prevent, Mol Immunol Sect, Atlanta, GA 30333 USA
[4] Ctr Dis Control & Prevent, Virol & Rickettsial Branch, Atlanta, GA 30333 USA
[5] Bristol Myers Squibb Co, Lexington, KY 40504 USA
[6] Univ Kentucky, Coll Pharm, Lexington, KY 40504 USA
关键词
fluoroquinolones; Rickettsia; Bartonella; in vitro;
D O I
10.1016/S0924-8579(01)00388-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro susceptibilities of Bartonella and Rickettsia spp. to different concentrations of ciprofloxacin, levofloxacin, ofloxacin and sparfloxacin in Vero cell cultures, were determined by enumeration of immunofluorescent-stained bacilli. After incubation in a CO2-enriched atmosphere, inocula were replaced and tested with media containing 12 different concentrations of each antibiotic in replicate for each species and the monolayers were re-incubated. Growth status was determined by evaluation of immunofluorescent staining bacilli. Effective inhibitory antibiotic dilution endpoints were determined by counting Bartonella- and Rickettsia-specific fluorescent foci across a range of antibiotic dilutions with an epi-fluorescent microscope, and were compared with an antibiotic-negative control, Based upon the use of C-max:MIC and AUC:MIC data, levofloxacin exhibited activity against Bartonella elizabethae and B. quintana. (C) 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 47 条
[1]   BARTONELLA-HENSELAE AND BARTONELLA-QUINTANA ADHERENCE TO AND ENTRY INTO CULTURED HUMAN EPITHELIAL-CELLS [J].
BATTERMAN, HJ ;
PEEK, JA ;
LOUTIT, JS ;
FALKOW, S ;
TOMPKINS, LS .
INFECTION AND IMMUNITY, 1995, 63 (11) :4553-4556
[2]   Chronic Bartonella quintana bacteremia in homeless patients [J].
Brouqui, P ;
Lascola, B ;
Roux, V ;
Raoult, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (03) :184-189
[3]   Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses [J].
Chien, SC ;
Rogge, MC ;
Gisclon, LG ;
Curtin, C ;
Wong, F ;
Natarajan, J ;
Williams, RR ;
Fowler, CL ;
Cheung, WK ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2256-2260
[4]   BARTONELLA HENSELAE PREVALENCE IN DOMESTIC CATS IN CALIFORNIA - RISK-FACTORS AND ASSOCIATION BETWEEN BACTEREMIA AND ANTIBODY-TITERS [J].
CHOMEL, BB ;
ABBOTT, RC ;
KASTEN, RW ;
FLOYDHAWKINS, KA ;
KASS, PH ;
GLASER, CA ;
PEDERSEN, NC ;
KOEHLER, JE .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (09) :2445-2450
[5]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[6]   ROCHALIMAEA-ELIZABETHAE SP-NOV ISOLATED FROM A PATIENT WITH ENDOCARDITIS [J].
DALY, JS ;
WORTHINGTON, MG ;
BRENNER, DJ ;
MOSS, CW ;
HOLLIS, DG ;
WEYANT, RS ;
STEIGERWALT, AG ;
WEAVER, RE ;
DANESHVAR, MI ;
OCONNOR, SP .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (04) :872-881
[7]   SYNDROME OF ROCHALIMAEA-HENSELAE ADENITIS SUGGESTING CAT SCRATCH DISEASE [J].
DOLAN, MJ ;
WONG, MT ;
REGNERY, RL ;
JORGENSEN, JH ;
GARCIA, M ;
PETERS, J ;
DREHNER, D .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (05) :331-336
[8]   PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].
DRUSANO, GL ;
JOHNSON, DE ;
ROSEN, M ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490
[9]   Rats of the genus Rattus are reservoir hosts for pathogenic Bartonella species:: An Old World origin for a New World disease? [J].
Ellis, BA ;
Regnery, RL ;
Beati, L ;
Bacellar, F ;
Rood, M ;
Glass, GG ;
Marston, E ;
Ksiazek, TG ;
Jones, D ;
Childs, JE .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :220-224
[10]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081